List of Tables
Table 1. Global Implantable Ophthalmic Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Implantable Ophthalmic Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Implantable Ophthalmic Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Implantable Ophthalmic Drugs Sales (K Dose) of Key Manufacturers (2021–2026)
Table 5. Global Implantable Ophthalmic Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Implantable Ophthalmic Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Implantable Ophthalmic Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Implantable Ophthalmic Drugs Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Implantable Ophthalmic Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Implantable Ophthalmic Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Implantable Ophthalmic Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Implantable Ophthalmic Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Implantable Ophthalmic Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Implantable Ophthalmic Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Implantable Ophthalmic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Implantable Ophthalmic Drugs Sales by Region (K Dose), 2021–2026
Table 18. Global Implantable Ophthalmic Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Implantable Ophthalmic Drugs Sales by Region (K Dose), 2027–2032
Table 20. Global Implantable Ophthalmic Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Implantable Ophthalmic Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Implantable Ophthalmic Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Implantable Ophthalmic Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Implantable Ophthalmic Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Implantable Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Implantable Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 27. North America Implantable Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 28. North America Implantable Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Implantable Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Implantable Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Implantable Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 32. Europe Implantable Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 33. Europe Implantable Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Implantable Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Implantable Ophthalmic Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Implantable Ophthalmic Drugs Sales by Region (K Dose), 2021–2026
Table 37. Asia Pacific Implantable Ophthalmic Drugs Sales by Region (K Dose), 2027–2032
Table 38. Asia Pacific Implantable Ophthalmic Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Implantable Ophthalmic Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Implantable Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Implantable Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 42. Latin America Implantable Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 43. Latin America Implantable Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Implantable Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Implantable Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Implantable Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 47. Middle East and Africa Implantable Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 48. Middle East and Africa Implantable Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Implantable Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Implantable Ophthalmic Drugs Sales (K Dose) by Type (2021–2026)
Table 51. Global Implantable Ophthalmic Drugs Sales (K Dose) by Type (2027–2032)
Table 52. Global Implantable Ophthalmic Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Implantable Ophthalmic Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Implantable Ophthalmic Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Implantable Ophthalmic Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Implantable Ophthalmic Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Implantable Ophthalmic Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Implantable Ophthalmic Drugs Price (US$/Dose) by Type (2021–2026)
Table 59. Global Implantable Ophthalmic Drugs Price (US$/Dose) by Type (2027–2032)
Table 60. Global Implantable Ophthalmic Drugs Sales (K Dose) by Application (2021–2026)
Table 61. Global Implantable Ophthalmic Drugs Sales (K Dose) by Application (2027–2032)
Table 62. Global Implantable Ophthalmic Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Implantable Ophthalmic Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Implantable Ophthalmic Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Implantable Ophthalmic Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Implantable Ophthalmic Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Implantable Ophthalmic Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Implantable Ophthalmic Drugs Price (US$/Dose) by Application (2021–2026)
Table 69. Global Implantable Ophthalmic Drugs Price (US$/Dose) by Application (2027–2032)
Table 70. Allergan (Durysta, Ozurdex) Company Information
Table 71. Allergan (Durysta, Ozurdex) Description and Business Overview
Table 72. Allergan (Durysta, Ozurdex) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 73. Allergan (Durysta, Ozurdex) Implantable Ophthalmic Drugs Product
Table 74. Allergan (Durysta, Ozurdex) Recent Developments/Updates
Table 75. Glaukos (Idose TR) Company Information
Table 76. Glaukos (Idose TR) Description and Business Overview
Table 77. Glaukos (Idose TR) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 78. Glaukos (Idose TR) Implantable Ophthalmic Drugs Product
Table 79. Glaukos (Idose TR) Recent Developments/Updates
Table 80. Graybug Vision (OTX-ITC) Company Information
Table 81. Graybug Vision (OTX-ITC) Description and Business Overview
Table 82. Graybug Vision (OTX-ITC) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 83. Graybug Vision (OTX-ITC) Implantable Ophthalmic Drugs Product
Table 84. Graybug Vision (OTX-ITC) Recent Developments/Updates
Table 85. Ocular Therapeutix (ReSure) Company Information
Table 86. Ocular Therapeutix (ReSure) Description and Business Overview
Table 87. Ocular Therapeutix (ReSure) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 88. Ocular Therapeutix (ReSure) Implantable Ophthalmic Drugs Product
Table 89. Ocular Therapeutix (ReSure) Recent Developments/Updates
Table 90. Novartis (Visudyne) Company Information
Table 91. Novartis (Visudyne) Description and Business Overview
Table 92. Novartis (Visudyne) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 93. Novartis (Visudyne) Implantable Ophthalmic Drugs Product
Table 94. Novartis (Visudyne) Recent Developments/Updates
Table 95. Eylea (Bayer, Regeneron) Company Information
Table 96. Eylea (Bayer, Regeneron) Description and Business Overview
Table 97. Eylea (Bayer, Regeneron) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 98. Eylea (Bayer, Regeneron) Implantable Ophthalmic Drugs Product
Table 99. Eylea (Bayer, Regeneron) Recent Developments/Updates
Table 100. Bausch&Lomb (Retisert, Vitrasert) Company Information
Table 101. Bausch&Lomb (Retisert, Vitrasert) Description and Business Overview
Table 102. Bausch&Lomb (Retisert, Vitrasert) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 103. Bausch&Lomb (Retisert, Vitrasert) Implantable Ophthalmic Drugs Product
Table 104. Bausch&Lomb (Retisert, Vitrasert) Recent Developments/Updates
Table 105. Alimera Sciences (Iluvien) Company Information
Table 106. Alimera Sciences (Iluvien) Description and Business Overview
Table 107. Alimera Sciences (Iluvien) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 108. Alimera Sciences (Iluvien) Implantable Ophthalmic Drugs Product
Table 109. Alimera Sciences (Iluvien) Recent Developments/Updates
Table 110. Mati (Evolute) Company Information
Table 111. Mati (Evolute) Description and Business Overview
Table 112. Mati (Evolute) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 113. Mati (Evolute) Implantable Ophthalmic Drugs Product
Table 114. Mati (Evolute) Recent Developments/Updates
Table 115. Roche (Vabysmo) Company Information
Table 116. Roche (Vabysmo) Description and Business Overview
Table 117. Roche (Vabysmo) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 118. Roche (Vabysmo) Implantable Ophthalmic Drugs Product
Table 119. Roche (Vabysmo) Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Implantable Ophthalmic Drugs Distributors List
Table 123. Implantable Ophthalmic Drugs Customers List
Table 124. Implantable Ophthalmic Drugs Market Trends
Table 125. Implantable Ophthalmic Drugs Market Drivers
Table 126. Implantable Ophthalmic Drugs Market Challenges
Table 127. Implantable Ophthalmic Drugs Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
Table 131. Authors List of This Report
List of Figures
Figure 1. Product Picture of Implantable Ophthalmic Drugs
Figure 2. Global Implantable Ophthalmic Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Implantable Ophthalmic Drugs Market Share by Type: 2025 & 2032
Figure 4. Vitreous Implant Type Product Picture
Figure 5. Lacrimal Gland Implant Type Product Picture
Figure 6. Micropump implantable type Product Picture
Figure 7. Others Product Picture
Figure 8. Global Implantable Ophthalmic Drugs Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Implantable Ophthalmic Drugs Market Share by Application: 2025 & 2032
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Home
Figure 13. Global Implantable Ophthalmic Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Implantable Ophthalmic Drugs Market Size (US$ Million), 2021–2032
Figure 15. Global Implantable Ophthalmic Drugs Sales (K Dose), 2021–2032
Figure 16. Global Implantable Ophthalmic Drugs Average Price (US$/Dose), 2021–2032
Figure 17. Implantable Ophthalmic Drugs Report Years Considered
Figure 18. Implantable Ophthalmic Drugs Sales Share by Manufacturers in 2025
Figure 19. Global Implantable Ophthalmic Drugs Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Implantable Ophthalmic Drugs Players: Market Share by Revenue in Implantable Ophthalmic Drugs in 2025
Figure 21. Implantable Ophthalmic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Implantable Ophthalmic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Implantable Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 24. North America Implantable Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 25. United States Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Implantable Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 28. Europe Implantable Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 29. Germany Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Implantable Ophthalmic Drugs Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Implantable Ophthalmic Drugs Revenue Market Share by Region (2021–2032)
Figure 36. China Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Implantable Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 44. Latin America Implantable Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Implantable Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Implantable Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Implantable Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Implantable Ophthalmic Drugs by Type (2021–2032)
Figure 55. Global Revenue Market Share of Implantable Ophthalmic Drugs by Type (2021–2032)
Figure 56. Global Implantable Ophthalmic Drugs Price (US$/Dose) by Type (2021–2032)
Figure 57. Global Sales Market Share of Implantable Ophthalmic Drugs by Application (2021–2032)
Figure 58. Global Revenue Market Share of Implantable Ophthalmic Drugs by Application (2021–2032)
Figure 59. Global Implantable Ophthalmic Drugs Price (US$/Dose) by Application (2021–2032)
Figure 60. Implantable Ophthalmic Drugs Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
